LadRx Corporation (LADX)
USD 1.49
(-2.61%)
USD 1.49
(-2.61%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.2 Million USD | -0.92% |
| 2022 | 2.22 Million USD | -43.78% |
| 2021 | 3.95 Million USD | 23.86% |
| 2020 | 3.18 Million USD | 55.55% |
| 2019 | 2.05 Million USD | -20.02% |
| 2018 | 2.56 Million USD | -91.51% |
| 2017 | 30.2 Million USD | -20.5% |
| 2016 | 37.99 Million USD | 65.58% |
| 2015 | 22.94 Million USD | 29.04% |
| 2014 | 17.78 Million USD | -42.34% |
| 2013 | 30.83 Million USD | 206.37% |
| 2012 | 10.06 Million USD | -25.99% |
| 2011 | 13.6 Million USD | 121.9% |
| 2010 | 6.12 Million USD | -11.55% |
| 2009 | 6.92 Million USD | -45.12% |
| 2008 | 12.62 Million USD | -40.48% |
| 2007 | 21.21 Million USD | -19.91% |
| 2006 | 26.48 Million USD | 869.99% |
| 2005 | 2.73 Million USD | -16.83% |
| 2004 | 3.28 Million USD | 82.25% |
| 2003 | 1.8 Million USD | 36.03% |
| 2002 | 1.32 Million USD | 28.84% |
| 2001 | 1.02 Million USD | -17.14% |
| 2000 | 1.24 Million USD | -75.65% |
| 1999 | 5.09 Million USD | 168.16% |
| 1998 | 1.9 Million USD | -62.75% |
| 1997 | 5.1 Million USD | 155.0% |
| 1996 | 2 Million USD | 66.67% |
| 1995 | 1.2 Million USD | 71.43% |
| 1994 | 700 Thousand USD | -66.67% |
| 1993 | 2.1 Million USD | 31.25% |
| 1992 | 1.6 Million USD | 45.45% |
| 1991 | 1.1 Million USD | 22.22% |
| 1990 | 900 Thousand USD | -77.5% |
| 1989 | 4 Million USD | -52.38% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.87 Million USD | -14.74% |
| 2024 Q2 | 1.82 Million USD | -2.57% |
| 2023 FY | 2.2 Million USD | -0.92% |
| 2023 Q3 | 2.1 Million USD | -4.58% |
| 2023 Q1 | 3.03 Million USD | 36.72% |
| 2023 Q4 | 2.2 Million USD | 4.78% |
| 2023 Q2 | 2.2 Million USD | -27.52% |
| 2022 Q4 | 2.22 Million USD | -5.19% |
| 2022 FY | 2.22 Million USD | -43.78% |
| 2022 Q1 | 3.28 Million USD | -16.8% |
| 2022 Q2 | 2.74 Million USD | -16.41% |
| 2022 Q3 | 2.34 Million USD | -14.73% |
| 2021 FY | 3.95 Million USD | 23.86% |
| 2021 Q2 | 2.8 Million USD | -7.36% |
| 2021 Q3 | 7.08 Million USD | 152.42% |
| 2021 Q1 | 3.02 Million USD | -5.0% |
| 2021 Q4 | 3.95 Million USD | -44.25% |
| 2020 Q1 | 2.7 Million USD | 31.86% |
| 2020 FY | 3.18 Million USD | 55.55% |
| 2020 Q2 | 2.76 Million USD | 2.28% |
| 2020 Q3 | 5.15 Million USD | 86.38% |
| 2020 Q4 | 3.18 Million USD | -38.12% |
| 2019 FY | 2.05 Million USD | -20.02% |
| 2019 Q3 | 3.13 Million USD | 68.79% |
| 2019 Q1 | 2.35 Million USD | -7.95% |
| 2019 Q2 | 1.85 Million USD | -21.38% |
| 2019 Q4 | 2.05 Million USD | -34.53% |
| 2018 FY | 2.56 Million USD | -91.51% |
| 2018 Q1 | 21.87 Million USD | -27.57% |
| 2018 Q4 | 2.56 Million USD | -75.39% |
| 2018 Q2 | 18.59 Million USD | -14.99% |
| 2018 Q3 | 10.41 Million USD | -43.99% |
| 2017 Q4 | 30.2 Million USD | 6.44% |
| 2017 Q3 | 28.37 Million USD | -27.49% |
| 2017 Q2 | 39.13 Million USD | 2.38% |
| 2017 Q1 | 38.22 Million USD | 0.61% |
| 2017 FY | 30.2 Million USD | -20.5% |
| 2016 Q4 | 37.99 Million USD | -5.75% |
| 2016 Q1 | 41.76 Million USD | 82.0% |
| 2016 Q2 | 36.97 Million USD | -11.46% |
| 2016 Q3 | 40.31 Million USD | 9.02% |
| 2016 FY | 37.99 Million USD | 65.58% |
| 2015 FY | 22.94 Million USD | 29.04% |
| 2015 Q1 | 21.99 Million USD | 23.7% |
| 2015 Q3 | 13.22 Million USD | -34.74% |
| 2015 Q2 | 20.27 Million USD | -7.83% |
| 2015 Q4 | 22.94 Million USD | 73.45% |
| 2014 Q3 | 18.61 Million USD | -17.27% |
| 2014 Q1 | 16.79 Million USD | -45.53% |
| 2014 Q4 | 17.78 Million USD | -4.48% |
| 2014 FY | 17.78 Million USD | -42.34% |
| 2014 Q2 | 22.49 Million USD | 33.94% |
| 2013 Q2 | 8.72 Million USD | -19.98% |
| 2013 FY | 30.83 Million USD | 206.37% |
| 2013 Q1 | 10.9 Million USD | 8.37% |
| 2013 Q4 | 30.83 Million USD | 131.43% |
| 2013 Q3 | 13.32 Million USD | 52.65% |
| 2012 Q3 | 20.6 Million USD | -23.1% |
| 2012 Q1 | 18.93 Million USD | 39.26% |
| 2012 FY | 10.06 Million USD | -25.99% |
| 2012 Q4 | 10.06 Million USD | -51.14% |
| 2012 Q2 | 26.79 Million USD | 41.45% |
| 2011 FY | 13.6 Million USD | 121.9% |
| 2011 Q3 | 16.32 Million USD | 139.31% |
| 2011 Q2 | 6.82 Million USD | -20.84% |
| 2011 Q1 | 8.61 Million USD | 40.63% |
| 2011 Q4 | 13.6 Million USD | -16.71% |
| 2010 Q3 | 6.9 Million USD | 22.78% |
| 2010 Q4 | 6.12 Million USD | -11.25% |
| 2010 Q1 | 7.34 Million USD | 5.99% |
| 2010 FY | 6.12 Million USD | -11.55% |
| 2010 Q2 | 5.62 Million USD | -23.42% |
| 2009 Q3 | 7.06 Million USD | -29.08% |
| 2009 FY | 6.92 Million USD | -45.12% |
| 2009 Q1 | 12.51 Million USD | -0.9% |
| 2009 Q2 | 9.95 Million USD | -20.41% |
| 2009 Q4 | 6.92 Million USD | -1.89% |
| 2008 FY | 12.62 Million USD | -40.48% |
| 2008 Q2 | 14.77 Million USD | -13.87% |
| 2008 Q4 | 12.62 Million USD | -26.03% |
| 2008 Q3 | 17.06 Million USD | 15.57% |
| 2008 Q1 | 17.14 Million USD | -19.16% |
| 2007 Q4 | 21.21 Million USD | -5.15% |
| 2007 Q1 | 25.27 Million USD | -4.56% |
| 2007 FY | 21.21 Million USD | -19.91% |
| 2007 Q2 | 23.62 Million USD | -6.52% |
| 2007 Q3 | 22.36 Million USD | -5.35% |
| 2006 Q2 | 3.21 Million USD | 29.78% |
| 2006 FY | 26.48 Million USD | 869.99% |
| 2006 Q1 | 2.47 Million USD | -9.21% |
| 2006 Q3 | 26.42 Million USD | 721.37% |
| 2006 Q4 | 26.48 Million USD | 0.22% |
| 2005 Q1 | 2.97 Million USD | -9.49% |
| 2005 Q2 | 3.27 Million USD | 10.09% |
| 2005 Q3 | 2.06 Million USD | -36.82% |
| 2005 FY | 2.73 Million USD | -16.83% |
| 2005 Q4 | 2.73 Million USD | 32.12% |
| 2004 FY | 3.28 Million USD | 82.25% |
| 2004 Q1 | 2.02 Million USD | 12.37% |
| 2004 Q4 | 3.28 Million USD | 15.24% |
| 2004 Q2 | 2.59 Million USD | 28.2% |
| 2004 Q3 | 2.84 Million USD | 9.77% |
| 2003 Q3 | 1.23 Million USD | 6.77% |
| 2003 Q4 | 1.8 Million USD | 45.77% |
| 2003 FY | 1.8 Million USD | 36.03% |
| 2003 Q1 | 1.22 Million USD | -7.54% |
| 2003 Q2 | 1.15 Million USD | -5.48% |
| 2002 Q2 | 703.71 Thousand USD | -5.77% |
| 2002 FY | 1.32 Million USD | 28.84% |
| 2002 Q3 | 600.22 Thousand USD | -14.71% |
| 2002 Q1 | 746.8 Thousand USD | -27.34% |
| 2002 Q4 | 1.32 Million USD | 120.63% |
| 2001 Q1 | 813.72 Thousand USD | -34.4% |
| 2001 FY | 1.02 Million USD | -17.14% |
| 2001 Q4 | 1.02 Million USD | 71.43% |
| 2001 Q3 | 599.58 Thousand USD | -9.73% |
| 2001 Q2 | 664.22 Thousand USD | -18.37% |
| 2000 Q4 | 1.24 Million USD | 0.41% |
| 2000 Q3 | 1.23 Million USD | -19.38% |
| 2000 FY | 1.24 Million USD | -75.65% |
| 2000 Q1 | 2.02 Million USD | -60.3% |
| 2000 Q2 | 1.53 Million USD | -24.25% |
| 1999 Q2 | 1.6 Million USD | -15.79% |
| 1999 FY | 5.09 Million USD | 168.16% |
| 1999 Q3 | 1.8 Million USD | 12.5% |
| 1999 Q1 | 1.9 Million USD | 0.0% |
| 1999 Q4 | 5.09 Million USD | 183.06% |
| 1998 Q4 | 1.9 Million USD | 58.33% |
| 1998 Q3 | 1.2 Million USD | 0.0% |
| 1998 Q1 | 3.1 Million USD | -39.22% |
| 1998 Q2 | 1.2 Million USD | -61.29% |
| 1998 FY | 1.9 Million USD | -62.75% |
| 1997 Q2 | 2.7 Million USD | 0.0% |
| 1997 Q4 | 5.1 Million USD | 50.0% |
| 1997 Q1 | 2.7 Million USD | 35.0% |
| 1997 FY | 5.1 Million USD | 155.0% |
| 1997 Q3 | 3.4 Million USD | 25.93% |
| 1996 FY | 2 Million USD | 66.67% |
| 1996 Q4 | 2 Million USD | 122.22% |
| 1996 Q1 | 800 Thousand USD | -33.33% |
| 1996 Q2 | 900 Thousand USD | 12.5% |
| 1996 Q3 | 900 Thousand USD | 0.0% |
| 1995 Q2 | 800 Thousand USD | 100.0% |
| 1995 Q4 | 1.2 Million USD | 9.09% |
| 1995 Q1 | 400 Thousand USD | -42.86% |
| 1995 FY | 1.2 Million USD | 71.43% |
| 1995 Q3 | 1.1 Million USD | 37.5% |
| 1994 Q2 | 1.8 Million USD | 20.0% |
| 1994 Q1 | 1.5 Million USD | -28.57% |
| 1994 Q4 | 700 Thousand USD | -76.67% |
| 1994 FY | 700 Thousand USD | -66.67% |
| 1994 Q3 | 3 Million USD | 66.67% |
| 1993 Q1 | 1.2 Million USD | -25.0% |
| 1993 Q2 | 900 Thousand USD | -25.0% |
| 1993 Q4 | 2.1 Million USD | 110.0% |
| 1993 Q3 | 1 Million USD | 11.11% |
| 1993 FY | 2.1 Million USD | 31.25% |
| 1992 Q1 | 300 Thousand USD | -72.73% |
| 1992 Q4 | 1.6 Million USD | 45.45% |
| 1992 Q2 | 800 Thousand USD | 166.67% |
| 1992 Q3 | 1.1 Million USD | 37.5% |
| 1992 FY | 1.6 Million USD | 45.45% |
| 1991 Q3 | 1 Million USD | 11.11% |
| 1991 FY | 1.1 Million USD | 22.22% |
| 1991 Q1 | 1.2 Million USD | 33.33% |
| 1991 Q2 | 900 Thousand USD | -25.0% |
| 1991 Q4 | 1.1 Million USD | 10.0% |
| 1990 Q1 | 1.5 Million USD | -62.5% |
| 1990 Q3 | 1 Million USD | -9.09% |
| 1990 Q4 | 900 Thousand USD | -10.0% |
| 1990 Q2 | 1.1 Million USD | -26.67% |
| 1990 FY | 900 Thousand USD | -77.5% |
| 1989 FY | 4 Million USD | -52.38% |
| 1989 Q4 | 4 Million USD | 263.64% |
| 1989 Q3 | 1.1 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -7921.463% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 76.753% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 96.964% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -172.075% |
| Rebus Holdings, Inc. | 5.24 Million USD | 58.021% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 96.271% |
| Qrons Inc. | 1.48 Million USD | -47.814% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -79.457% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 97.063% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -4823.322% |
| Skye Bioscience, Inc. | 14.07 Million USD | 84.363% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 95.872% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 77.035% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -421.986% |
| SQZ Biotechnologies Company | 50.03 Million USD | 95.602% |
| Intellipharmaceutics International Inc. | 12 Million USD | 81.676% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 42.865% |
| Mesoblast Limited | 188.44 Million USD | 98.832% |
| Marizyme, Inc. | 26.67 Million USD | 91.751% |
| Genus plc | 485 Million USD | 99.546% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 62.337% |
| Pharming Group N.V. | 244.07 Million USD | 99.098% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -9.472% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 12.55% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 42.091% |
| ContraFect Corporation | 32.53 Million USD | 93.236% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -11.064% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 42.51% |
| IMV Inc. | 37.93 Million USD | 94.199% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 81.317% |
| MultiCell Technologies, Inc. | 1617.67 USD | -135930.711% |
| ONE Bio Corp. | 27.49 Million USD | 91.997% |
| Accustem Sciences Inc. | 1.07 Million USD | -103.896% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 97.158% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -4.04% |
| Q BioMed Inc. | 8.13 Million USD | 72.943% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 97.347% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 57.238% |
| Biomind Labs Inc. | 1.49 Million USD | -46.838% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 98.146% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 75.664% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 88.043% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -53.469% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -1448.632% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -994.159% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 61.702% |
| GB Sciences, Inc. | 5.41 Million USD | 59.382% |
| Alpha Cognition Inc. | 7.16 Million USD | 69.287% |
| HST Global, Inc. | 593.59 Thousand USD | -270.713% |
| CSL Limited | 18.62 Billion USD | 99.988% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -74.757% |
| Halberd Corporation | 728.71 Thousand USD | -201.972% |
| Enzolytics Inc. | 365.26 Million USD | 99.398% |
| Agentix Corp. | 2.51 Million USD | 12.349% |
| Resverlogix Corp. | 67.39 Million USD | 96.735% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -162.364% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.505% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -28.386% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 91.108% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 81.513% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 39.961% |
| AVAX Technologies, Inc. | 3.99 Million USD | 44.901% |
| Zenith Capital Corp. | 27.56 Thousand USD | -7881.893% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.834% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -822.058% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 41.073% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -223.211% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 18.849% |
| Kadimastem Ltd | 3.5 Million USD | 37.215% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -3187.854% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 95.622% |
| BioStem Technologies, Inc. | 15.9 Million USD | 86.164% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -373.538% |
| Cell Source, Inc. | 15.8 Million USD | 86.079% |
| Regen BioPharma, Inc. | 5.45 Million USD | 59.68% |
| Regen BioPharma, Inc. | 5.45 Million USD | 59.68% |
| NovAccess Global Inc. | 7.86 Million USD | 72.006% |
| Affymax, Inc. | 8.87 Million USD | 75.194% |
| Itoco Inc. | 1.65 Million USD | -33.111% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -7.261% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 63.622% |
| Mobile Lads Corp. | 1.31 Million USD | -67.532% |
| CytoDyn Inc. | 127.89 Million USD | 98.279% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -5164.547% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -40.485% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 80.077% |
| SYBLEU INC | 681.41 Thousand USD | -222.936% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 63.937% |
| International Stem Cell Corporation | 5.27 Million USD | 58.3% |
| Bioxytran, Inc. | 3.24 Million USD | 32.281% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -251.629% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 52.34% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 94.632% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 90.117% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -8.647% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 59.83% |
| Neutra Corp. | 973.52 Thousand USD | -126.036% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 92.416% |
| PureTech Health plc | 125.58 Million USD | 98.248% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 41.431% |
| IXICO plc | 1.9 Million USD | -15.799% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 89.281% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 97.87% |
| CSL Limited | 18.62 Billion USD | 99.988% |
| Cellectis S.A. | 249.36 Million USD | 99.118% |